التفاصيل البيبلوغرافية
| العنوان: |
Research from Hospital Alvaro Cunqueiro Yields New Study Findings on Inflammatory Bowel Disease (P916 Off-label dose escalation of Ustekinumab in Inflammatory Bowel Disease patients. Incidence rate, timing, dosing patterns and outcomes). |
| المصدر: |
Immunotherapy Weekly; 2/15/2024, p1888-1888, 1p |
| مستخلص: |
A recent study conducted at Hospital Alvaro Cunqueiro in Vigo, Spain, examined the use of Ustekinumab (UST) in patients with inflammatory bowel disease (IBD). The study found that dose escalation of UST was a common and effective strategy for achieving response in IBD patients. The timing and patterns of dose escalation varied among participants, but patients who were initially scheduled to receive UST every 12 weeks required less dose escalation. The study highlights the need for further research to determine the optimal dosing strategy for UST in IBD patients. [Extracted from the article] |
|
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
